Question 1

ARQT vs JNJ: which stock scores better overall?

Accepted Answer

Based on Q·Score, Johnson & Johnson (JNJ) scores 7.1/10 versus Arcutis Biotherapeutics, Inc. (ARQT) at 7/10. The Q·Score measures five dimensions: Quality, Value, Growth, Safety, and Momentum. For informational purposes only — not financial advice.

Question 2

Which has better revenue growth: ARQT or JNJ?

Accepted Answer

Arcutis Biotherapeutics, Inc. (ARQT) scores higher on Growth (8.3/10 vs 5.1/10). Arcutis Biotherapeutics, Inc. reports revenue growth (81.5% YoY) while Johnson & Johnson reports (9.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.

Question 3

Is ARQT or JNJ more attractively valued?

Accepted Answer

Arcutis Biotherapeutics, Inc. (ARQT) scores higher on Value (9.1/10 vs 7.3/10). ARQT trades at 19.4× P/E versus JNJ at 17.9×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.

Question 4

What do analysts say about ARQT vs JNJ?

Accepted Answer

There are 8 analysts covering ARQT with a consensus price target of $34.75, and 24 analysts covering JNJ with a consensus target of $252.42. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.

Question 5

Which is more profitable: ARQT or JNJ?

Accepted Answer

Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 2.6/10). Net profit margin: ARQT at -4.3%, JNJ at 21.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.

Question 6

Which has stronger financial health: ARQT or JNJ?

Accepted Answer

Arcutis Biotherapeutics, Inc. (ARQT) scores higher on Financial Health (8.2/10 vs 6.5/10). Market beta: ARQT at 1.77, JNJ at 0.33. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.

Question 7

What are the market caps of ARQT and JNJ?

Accepted Answer

Arcutis Biotherapeutics, Inc. (ARQT) has a market capitalisation of $2.9B, while Johnson & Johnson (JNJ) has a market cap of $546.9B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.

Question 8

Do ARQT or JNJ pay dividends?

Accepted Answer

ARQT does not currently pay a dividend, while JNJ pays a dividend yield of 2.36%. Dividend yields fluctuate with share price and company payout decisions.

Arcutis Biotherapeutics, Inc. vs Johnson & Johnson — Stock Comparison

Q·Score Breakdown

Analyst Consensus

Fundamentals